cash flow from fondaparinux and debt funding, page-57

GSK (and other big pharmas, for that matter) might possibly find themselves in this situation with many dozens of other first mover generic drug companies - each a potential cash cow in their own right.

However, it might just be too difficult for big pharma to consider this each time an opportunity such as ACL comes up, unless it is a screaming standout (maybe ACL is in our eyes).

I agree that once the pipeline progresses a little further, ACL may very well start to stand out from the pack of opportunities.